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MixtureMany xenobiotics have been identiﬁed as in vitro androgen receptor (AR) antagonists, but information about their
ability to produce combined effects at low concentrations is missing. Such data can reveal whether joint effects at
the receptor are induced at low levels andmay support the prioritisation of in vivo evaluations and provide orien-
tations for the grouping of anti-androgens in cumulative risk assessment. Combinations of 30 AR antagonists from
a wide range of sources and exposure routes (pesticides, antioxidants, parabens, UV-ﬁlters, synthetic musks,
bisphenol-A, benzo(a)pyrene, perﬂuorooctane sulfonate and pentabromodiphenyl ether) were tested using a re-
porter gene assay (MDA-kb2). Chemicalswere combined at threemixture ratios, equivalent to single components'
effect concentrations that inhibit the action of dihydrotesterone by 1%, 10% or 20%. Concentration addition (CA)
and independent action were used to calculate additivity expectations. We observed complete suppression of
dihydrotestosterone effects when chemicals were combined at individual concentrations eliciting 1%, 10% or
20% AR antagonistic effect. Due to the large number of mixture components, the combined AR antagonistic effects
occurred at very low concentrations of individual mixture components. CA slightly underestimated the combined
effects at all mixture ratios. In conclusion, large numbers of AR antagonists from a wide variety of sources and ex-
posure routes have the ability of acting together at the receptor to produce joint effects at very low concentrations.
Signiﬁcant mixture effects are observed when chemicals are combined at concentrations that individually do not
induce observable AR antagonistic effects. Cumulative risk assessment for AR antagonists should apply grouping
criteria based on effects where data are available, rather than on criteria of chemical similarity.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Cryptorchidisms and hypospadias are the most frequent congenital
malformations in boys. Although there are marked differences in
regional prevalence, several countries have experienced increases in
the incidence of cryptorchidisms (reviewed in: Main et al., 2010) andion addition; DHT, dihydrotes-
concentrations that inhibit the
. Kortenkamp).
nmental Sciences, University of
. Open access under CC BY-NC-ND lichypospadias (Boisen et al., 2004; Nassar et al., 2007; Nelson et al., 2005;
Pierik et al., 2004). Alcohol consumption, low birth weight, premature
birth and diets lacking in protein (Pierik et al., 2004) are well recognised
risk factors, but these alone cannot explain the continuing rises in inci-
dence. Skakkebaek et al. (2001) have proposed that cryptorchidism and
hypospadias are part of the testicular dysgenesis syndrome, hypothesised
to arise from insufﬁcient androgen action in foetal life, and that exposures
to anti-androgenic chemicals are an etiological factor. Although evidence
for links between exposure to speciﬁc chemicals and testicular dysgenesis
syndrome in humans is currently limited (reviewed in: WHO, 2012),
support for the plausibility of an involvement of androgen receptor (AR)
antagonists comes from experimental studies using a developmental
toxicity model in the rat. In foetal life, steroidal androgens are key
drivers of the differentiation of the Wolfﬁan duct system into the vas
deferens, epididymis, seminal vesicles and external genitalia. Exposure
of male rats to AR antagonists and other anti-androgens in foetal life
leads to incomplete masculinisation and severe malformations of the
reproductive organs, similar to some of the disorders seen in humans,ense.
Table 1
Chemicals selected for mixture studies. Shown are effect concentrations (mole/L) for
individual mixture components required to produce 1% AR antagonistic effects (IC01).
The concentrations at which these chemicals are present in the three mixtures where
these produce a combined effect of 10% AR antagonism are also shown (“IC01 mix”,
“IC10 mix”, “IC20 mix”).
Individual Concentration in mixture at 10% inhibition
Compound IC01 IC01 mix IC10 mix IC20 mix
3-BC 4.50E−06 7.68E−07 8.26E−07 4.97E−07
4-MBC 7.63E−06 1.30E−06 1.10E−06 6.14E−07
AHTN 1.52E−06 2.60E−07 3.20E−07 2.35E−07
BDE100 7.72E−08 1.32E−08 2.37E−08 1.75E−08
Benzo(a)pyrene 2.93E−08 5.01E−09 4.15E−08 6.55E−08
Benzophenone 2 6.70E−08 1.14E−08 3.29E−08 3.24E−08
Benzophenone 3 3.63E−06 6.21E−07 4.67E−07 2.77E−07
BHA 1.31E−06 2.24E−07 2.59E−07 1.87E−07
BHT 1.86E−06 3.17E−07 1.12E−06 9.35E−07
Bisphenol A 4.08E−07 6.97E−08 6.90E−08 4.68E−08
Chlorpropham 2.59E−06 4.43E−07 3.77E−07 2.41E−07
Cyprodinil 3.83E−06 6.55E−07 7.42E−07 4.59E−07
Dimethomorph 6.01E−08 1.03E−08 1.12E−08 8.05E−09
Ethyl paraben 3.98E−05 6.80E−06 4.10E−06 2.18E−06
Fenhexamid 8.22E−08 1.41E−08 6.32E−08 6.07E−08
Fludioxonil 1.54E−07 2.64E−08 3.30E−08 2.50E−08
HHCB 3.83E−07 6.55E−08 1.15E−07 9.74E−08
Imazalil 2.91E−07 4.98E−08 1.24E−07 9.77E−08
Linuron 2.75E−07 4.70E−08 6.32E−08 5.03E−08
Methiocarb 2.28E−06 3.90E−07 3.26E−07 2.03E−07
Methyl paraben 2.69E−05 4.59E−06 4.25E−06 2.76E−06
n-Butyl paraben 1.73E−05 2.95E−06 1.91E−06 9.70E−07
n-Propyl paraben 3.22E−05 5.51E−06 3.03E−06 1.53E−06
PCB138 1.27E−06 2.17E−07 1.80E−07 1.14E−07
PFOS 4.89E−06 8.36E−07 7.64E−07 4.36E−07
Phenylphenol 3.28E−07 5.61E−08 1.31E−07 1.03E−07
Pirimiphos-methyl 1.07E−06 1.84E−07 2.31E−07 1.73E−07
Pyrimethanil 3.79E−06 6.48E−07 1.06E−06 8.83E−07
Tebuconazole 6.56E−07 1.12E−07 1.24E−07 8.79E−08
Vinclozolin 1.26E−08 2.15E−09 5.89E−09 4.93E−09
SUM (=IC10) 2.72E−05 2.19E−05 1.34E−05
Abbreviations: BDE = pentabromodiphenyl ether; BHA = butylated hydroxyanisole;
PFOS = perﬂuorooctane sulfonate; 3-BC = benzylidene camphor; 4-MBC = 4-
methylenbenzylidene camphor; BHT = butylated hydroxytoluol.
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et al., 2007). These observations have provided the stimulus to assess
human health risks associated with AR antagonists.
The realisation that humans are typically exposed to numerous anti-
androgens simultaneously (Schlumpf et al., 2010;Woodruff et al., 2011)
has motivated the consideration of possible combination effects. In
animal experiments, anti-androgens are known to produce combination
effects (Christiansen et al., 2009, 2012; Hass et al., 2007; Metzdorff et al.,
2007; Rider et al., 2008), but there are obvious limitations to studying the
joint effects of larger numbers of agents in vivo, even though such infor-
mation is essential for risk assessment. However, to predict the effects
of largemulti-componentmixtures on the basis of the toxicity of its com-
ponents will stretch the resources for in vivo studies. Such resource limi-
tations do not come into play with in vitro assays with AR responsive
reporter gene constructs and their use has considerably advanced our
knowledge about the ways in which AR antagonists can act together
(Birkhoj et al., 2004; Ermler et al., 2011; Kjærstad et al., 2010; Orton
et al., 2012). The experimental results with anti-androgen mixtures
have stimulated interest in cumulative risk assessment for these
chemicals (NRC, 2008). Cumulative risk assessment cannot proceed
without addressing which chemicals should be considered together,
and which criteria should be used to build common assessment groups.
In theUSA, chemicalswith similar structures have been grouped together
(USEPA, 2006a, 2006b, 2006c, 2007, 2011), butmore recently, alternative
approaches which place an emphasis on common adverse outcomes
have been suggested (EFSA, 2013; NRC, 2008). Although the data pub-
lished in the literature show that combination effects can arise from
quite diverse AR antagonists (Ermler et al., 2010; Orton et al., 2012), the
development of common assessment groups for these agentswill also re-
quire evidence that chemicals from a range of sources and exposure
routes can together antagonise the AR.
A combination of 30 AR antagonists was selected for testing, which
comprised 13 pesticides (herbicides, insecticides, fungicides) and 17
non-pesticides (antioxidants, parabens, UV-ﬁlters, synthetic musks,
bisphenol A (BPA), benzo(a)pyrene (BaP), perﬂuorooctane sulfonate
(PFOS) and pentabromodiphenyl ether (BDE100)). While human expo-
sure to the 13 selected pesticides was inferred from their wide use in
the EU (no biomonitoring data available: Orton et al., 2011), the 17
non-pesticideswere selected based on their high levels in human tissues
(Ermler et al., 2011). These chemicals together covered a wide range of
sources and exposures routes, including oral (pesticides, antioxidants:
McKinlay et al., 2008; BPA: Geens et al., 2012), dermal (UV ﬁlters:
Giokas et al., 2007; synthetic musks: Roosens et al., 2007; parabens:
Darbre and Harvey, 2008; brominated ﬂame retardants: Buttke et al.,
2013) and inhalation (BaP: Ravindra et al., 2008). The large number of
chemicals included in our mixtures provided the opportunity to assess
the combined effects of AR antagonists at low concentrations, particu-
larly at concentrations where the effects of the single components are
below the detection limit of the assay. Such data is important to contrib-
ute to future efforts of modelling the effects of untested mixtures
composed of xenobiotics with known anti-androgenicity at relevant
concentrations.
We used a ﬁxed-mixture ratio experimental design, in which we
employed two common concepts for predicting the (additive) effects
of mixtures: concentration addition (CA, also called dose addition)
and independent action (IA, also called response addition). CA assumes
that all compounds have a similar mechanism of action (e.g., binding to
the same receptor), whereas IA presumes that all mixture components
affect the same endpoint via different sites or modes of action (dissimilar
action). Both additivity models assume that there is no interaction
between the compounds, neither on a physico-chemical level nor in
their toxicokinetics and toxicodynamics. If this condition is fulﬁlled,
agreement between observed and expected outcomes can be expected
(for review see: Kortenkamp, 2007). Although there are exceptions
(Christiansen et al., 2009; Kjærstad et al., 2010), the majority of studies
have shown that the effects of mixtures can be approximated fairly wellbyusing the concept of CAwhen the effects of individualmixture compo-
nents are known (Christiansen et al., 2008; Ermler et al., 2011; Hass
et al., 2007; Howdeshell et al., 2008; Orton et al., 2012). In light of the
features of the in vitro AR antagonist assay used here, it can be
hypothesised that CA would be an appropriate prediction concept,
but we also calculated mixture effects by using IA for comparative
purposes.
To realise the aims of our low dose mixture experiments, we had to
develop criteria forwhat should constitute a “lowdose”. One optionwas
to choose concentrations of all single mixture components associated
with effect magnitudes around the limit of detection of the MDA-kb2
assay. We previously reported that the statistical power afforded by
the MDA-kb2 assay in our laboratory can reliably detect a reduction
by 10% of the effects of the reference androgen dihydrotesterone
(DHT) (Ermler et al., 2010). Therefore, we tested two effects levels
(10% inhibition and 20% inhibition) where associated concentrations
of individual components could be detected statistically. In addition,
we were interested in examining effects at 1% inhibition, as this results
in very low concentrations of individual pollutants (range: 0.012–
39.8 μM, Table 1), which may be more environmentally relevant. Since
such small effects cannot be measured directly with the MDA-kb2
assay, the respective effect concentrations had to be estimated by regres-
sion. This is the ﬁrst study to investigate mixtures of such a large number
of components and how such mixtures behave when combined at very
low levels.
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Test compound selection. We have previously shown that 24 current
use and environmentally relevant pesticides are AR antagonists (Orton
et al., 2011), and that mixtures of these pesticides act in combination
(Orton et al., 2012). We have also shown that 17 non-pesticidal pollut-
ants are anti-androgenic and produce combination effects (Ermler
et al., 2011). In the present study, we have combined the 13 pesticides
assessed earlier (Orton et al., 2011) with a mixture of 17 non-pesticide
AR antagonists (Ermler et al., 2011). The selected chemicals are listed
in Table 1.
Chemicals. Dihydrotestosterone (DHT; N97% purity) was purchased
from Steraloids Ltd. (Croydon, Surrey, UK). Dimethomorph and
methiocarbwere purchased fromGreyhoundChromatography andAllied
Chemicals (N98.7% purity; Birkenhead, Merseyside, UK). Ethyl paraben
and methyl paraben were purchased from Acros Organics (N99%
purity; Geel, Belgium) and hexahydrohexamethylcyclopentabenzopyran
(galaxolide/HHCB), 6-acetyl-1,1,2,4,4,7-hexamethyltetraline (tonalide/
AHTN) and 2,2′,4,4′,6-pentabromodiphenyl ether (BDE100) from LGC
Promochem (N98% purity; Teddington, Middlesex, UK). 3-Benzylidene
camphor (3-BC) was purchased from Induchem AG (N97% purity;
Volketswil, Switzerland) and 4-methylenbenzylidene camphor
(4-MBC) from Merck & Co (N98% purity; Hertfordshire, UK). 2,2′,
3,4,4′,5′-Hexachlorobiphenyl (PCB138) was purchased from Riedel-
de-Haen (N99% purity; Hanover, Germany). All other chemicals (N97%
purity)were purchased from SigmaAldrich (Poole, Dorset, UK). Ethanol
(N99.7% purity) was obtained from VWR International Ltd. (Leicester-
shire, UK). All test compounds were dissolved in ethanol to make
stock solutions to be used in the assays.
MDA-kb2 assay. MDA-kb2 cells are a human breast cancer cell line
stably transfectedwith an androgen responsive ﬁreﬂy luciferase reporter
gene (American Tissue Culture Collection, ATCC, LGC standards,
Teddington, UK: Wilson et al., 2002). We have adapted and optimized
the assay to meet the demands of experimental mixture studies, in
terms of high reproducibility and minimal experiment-to-experiment
variation. Details of the procedure, together with power analyses were
published previously (Ermler et al., 2010). Brieﬂy, cells were seeded at
a concentration of 1 × 105 cells/mL in phenol red-free Leibowitz-15me-
dium (Invitrogen Ltd., Paisley, UK) containing 10% (charcoal-stripped)
foetal calf serum (Invitrogen Ltd.) in white luminometer plates. After
28 h of treatment, luciferase activity was determined with SteadyGlo
assay reagent (Promega UK Ltd., Southampton, Hampshire, UK) and
measured in a plate reader (FLUOstar Optima, BMG Labtech GmbH,
Offenburg, Germany). To obtain concentration–response relationships,
the effects of test compounds on the luminescence produced by ﬁxed
concentrations (0.25 nMDHT)were investigated. A reduction of DHT lu-
minescence in concentration ranges not associated with cytotoxicity
(see below) was interpreted as evidence for AR antagonism. Cells
were exposed to eight serial dilutions of the selected chemicals either
in the presence or the absence of DHT (0.25 nM). Concentration ranges
in which the test chemicals exhibited AR antagonistic effects were
established initially through screening in the range of 1.17 nM–
150 μM, followed by testing of ﬁnely spaced concentrations according
to the potency and toxicity of each individual mixture component.
The following controls were run on each plate: media, media with eth-
anol (0.25%), DHT (0.25 nM) andDHT serial dilutions (0.009–20 nM) in
media with ethanol (0.25%). As positive control for an AR antagonist we
used procymidone (0.005–3.2 μM) with DHT (0.25 nM) in media and
ethanol (0.25%). All concentrations were tested in duplicate over two
plates within each experiment, and were repeated in at least four inde-
pendent experimental sessions. To enable the pooling of data from dif-
ferent experimental sessions, luminescence readings were normalised
to the readings with DHT alone (0.25 nM) and this was taken as the
maximum response (100%). Solvent only (ethanol) controls wereused to deﬁne the minimum response (0%), as described (Ermler
et al., 2011; Orton et al., 2012).
Cytotoxicity as a confounding factor. The MDA-kb2 assay measures
the decrease in luminescence induction by the DHT agonist that occurs
as a result of competitive receptor antagonism. Since the luminescence
signal can also be driven down by cytotoxicity, it is important to distin-
guish antagonism from interfering cytotoxicity. Cytotoxicity was deter-
mined in treatments without DHT and reductions in luminescence
relative to the solvent (ethanol) controls were measured. The cytotoxic
range became apparent from a down-turn of the luminescence readings
below the values of solvent controls (shown as insets in Fig. 1). Treat-
ments in the absence of DHT also revealed the AR agonist properties of
some of the tested chemicals at higher concentrations. In these cases,
cytotoxicity was evaluated in relation to the maximal AR agonistic
response. This is an indirect method for determining cytotoxicity in re-
porter gene assays, and has been reported in the MDA-kb2 assay several
times previously (Ermler et al., 2011, 2010; Korner et al., 2004; Orton
et al., 2011, 2012).
Test mixtures and prediction of combination effects. A total of 30
chemicals were combined (13 pesticides: ﬂudioxonil, fenhexamid,
ortho-phenylphenol, tebuconazole, dimethomorph, imazalil, methiocarb,
pirimiphos-methyl, cyprodinil, pyrimethanil, vinclozolin, chlorpropham,
linuron; 17 non-pesticides: bisphenol-A, n-butyl paraben, n-propyl
paraben, perﬂuorooctane sulfonate (tetrabutylammonium salt: PFOS),
2,2′,4,4′-tetrahydroxybenzophenone (benzophenone 2), 2-hydroxy-4-
methoxybenzophenone (benzophenone 3), butylated hydroxyanisole
(BHA), butylated hydroxytoluol (BHT), benzo(α)pyrene (BaP), ethyl
paraben, methyl paraben, galaxolide, tonalide, BDE100, 3-BC, 4-MBC
and PCB138). Three mixture stock solutions with ﬁxed mixture ratios
were prepared. The mixture ratios were chosen in proportion to the
concentrations of the individual mixture components that led to a sup-
pression of DHT effects by 1%, 10% or 20%, here termed inhibitory concen-
trations IC01, IC10 or IC20. Accordingly, the resulting mixtures are
referred to as the IC01mix, the IC10mix or the IC20mix. The composition
of the mixtures is shown in Supplemental material, Table S1. We utilised
the concentration–response relationships of 30AR antagonistic chemicals
(Supplementalmaterial, Table S2) to predict the combined effects of three
30 component mixtures with different mixture ratios (IC01, IC10, IC20).
The IC01 mixtures allowed us to assess directly whether mixture effects
would arise when all components were combined at their individual
IC01 concentrations. The other mixture ratios were chosen to assess
whether the predictability of combination effectswas affected bymixture
ratio.We selected the IC20mixture because this represents an effectmag-
nitude where individual components can be reliably identiﬁed as AR an-
tagonists because their effects are signiﬁcantly different from the effects
seen with cells primed with DHT in the absence of test chemicals. We
have previously shown that such effect sizes are demonstrable with the
experimental power afforded by the MDA-kb2 assay (Ermler et al.,
2010). The IC10 mixture ratio was chosen as a value intermediate
between the above two ratios. A list of regressionmodels for the concen-
tration–response relationships of the individual chemicals, together with
estimates of their IC10 can be found in Table S2 Supplemental material.
Each mixture stock solution was serially diluted and tested at least
3 times in separate experimental sessions and using new stock solu-
tions for each session. Two experimenters conducted the experiments
separately.
The mathematical and statistical procedures used for calculating
mixture effects according to concentration addition (CA) and indepen-
dent action (IA) follow those described in Faust et al. (2001). Due to
themathematical features of CA, the concept cannot be used to calculate
effect concentrations for themixture that exceed themaximal AR antag-
onistic effect of the least efﬁcacious compound present in the combina-
tion. For the mixtures investigated here, this limitation was introduced
by BaP which showed AR antagonistic effects of a magnitude not
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tion level of 40% (θmin = 0.59, see Table 2 in Supplementary material).
To construct CA prediction curves that covered the entire range of an-
tagonistic effects, we developed a pragmatic solution that extrapolatesthe toxic units (as deﬁned in Faust et al., 2001) of sub-maximalmixture
components to effect levels beyond their maximal efﬁcacy. In short, the
contribution of BaP to the overall mixture effect was extrapolated either
(i) by setting its toxic unit to zero (assuming no contribution) or (ii) by
Table 2
Statistical uncertainty of predicted and observed AR antagonistic effect concentrations for 30 compound mixtures.
% suppression of DHT effect AR antagonistic effect concentrations of mixtures [mole/L]
Observed Predicted by CA Predicted by IA
Mean 95% CI Mean 95% CI Mean 95% CI
IC01 mix, as deﬁned in Table S1
10% 2.72E−5 [2.22E−5–3.22E−5] 1.50E−5 [1.36E−5–1.56E−5] 1.09E−4 [6.50E−5–1.09E−4]
20% 3.76E−5 [3.23E−5–4.29E−5] 2.21E−5 [2.08E−5–2.28E−5] 1.44E−4 [1.06E−4–1.47E−4]
50% 6.34E−5 [5.77E−5–6.87E−5] 4.41E−5–4.42E−5* 2.04E−4 [1.78E−4–2.12E−4]
IC10 mix, as deﬁned in Table S1
10% 2.19E−5 [1.91E−5–2.48E−5] 1.04E−5 [9.31E−6–1.09E−5] 4.49E−5 [2.38E−5–4.87E−5]
20% 3.00E−5 [2.69E−5–3.31E−5] 1.67E−5 [1.57E−5–1.72E−5] 7.54E−5 [5.02E−5–7.91E−5]
50% 5.52E−5 [5.13E−5–5.92E−5] 3.73E−5–3.74E−5* 1.45E−4 [1.20E−4–1.53E−4]
IC20 mix, as deﬁned in Table S1
10% 1.34E−5 [9.11E−6–1.76E−5] 8.67E−6 [7.55E−6–9.13E−6] 2.93E−5 [1.48E−5–3.36E−5]
20% 2.06E−5 [1.58E−5–2.48E−5] 1.46E−5 [1.37E−5–1.51E−5] 5.29E−5 [3.53E−5–5.78E−5]
50% 4.66E−5 [4.23E−5–5.07E−5] 3.62E−5–3.63E−5* 1.14E−4 [9.37E−5–1.22E−4]
CA — concentration addition, IA — independent action, CI — conﬁdence interval; *the lowest effect level estimated for benzo[a]pyrene is 59%, preventing an exact calculation of the
expected AR antagonistic mixture effect concentration for 50%. Instead the compounds' contribution to the overall mixture effect was extrapolated either (i) by setting its toxic unit to
zero (assuming no contribution), or (ii) by setting its toxic unit to a maximumworst-case value (derived from ICmixture estimations for 40% effect levels). The higher values correspond
to (i) and the lower to (ii), deﬁning the range of possible CA predictions.
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mixture estimations for 40% effect levels). The higher values correspond
to (i) and the lower to (ii), deﬁning the range of possible CA predictions.
This approach uses the entire information of the dose–response func-
tions of the individual compounds, and makes no assumptions about a
common slope model parameter. The regression models for the experi-
mentally observed effects of the three mixtures are listed in Table S3 of
supplemental information, together with model parameters, estimated
AR antagonistic effect concentrations and effect concentrations for
androgenicity and cytotoxicity.
Statistics. To analyse AR antagonist action, raw luminescence
readings were normalised on a plate by plate basis to the means of
the positive DHT controls (n = 8 wells) and the solvent controls
(n = 8wells) whichwere placed on the same plate. Luminescence read-
ings from compounds tested in the absence of DHT were divided by the
mean of the solvent controls from the same plate and analysed for nega-
tive and positive trends (suggestive of cytotoxic or androgenic action, re-
spectively). All data from the same test compound were pooled and
statistical concentration response regression analyses were conducted
by using the best-ﬁt approach described by Scholze et al. (2001) to derive
inhibitory concentrations (IC) for androgenicity. To control for variations
between experiments, concentration response data were analysed by
using a generalised non-linear mixed modelling approach (Vonesh and
Chinchilli, 1996) with plate as a random effect modiﬁer for individual
effect data. If readings in the absence of DHT showed indications for cyto-
toxic or androgenic action, the non-monotonic concentration–response
relationship was modelled by non-parametric local regression methods
(Cleveland et al., 1988). From this robust ﬁttingmethodwe derived effect
concentrations (ECs) for androgenicity, with a 10% increase over the
mean solvent mean as theminimum effect criterion, and ECs for cytotox-
icity (if present) as 10% reduction of the maximal observed androgenicFig. 1. Predicted and observed anti-androgenic activity of mixtures composed of 30 AR antagoni
components individually associated with a 1% antagonistic effect, IC01 (A), a 10% antagonistic e
least four independent mixture experiments and are shown as black dots with error bars (m
Mixture effects were predicted by using concentration addition (CA) (solid green lines). The lig
does not contribute to themixture effect at antagonistic levels beyond 70% of the luminescence
alongside the CA and IA prediction curves indicate the 95% conﬁdence belts of the predictions. G
mixtures. Concentration ranges where the mixtures produced androgenic effects are highlighted
are shown as grey bars. Vertical dotted lines depict the mixture concentrations at which all in
antagonistic effects of 1% (A), 10% (B) and 20% (C). The inset graphs show androgenic effects
(solid grey line) and 95% conﬁdence belt (dotted grey line), the concentration axis showsmolar c
control effect. A down-turn of the curves below the horizontal line deﬁning control values (1 onaction. Data points associated with cytotoxicity were not included in re-
gression analysis for anti-androgenicity. Differences between predicted
and observed effect concentrations were deemed statistically signiﬁcant
when the 95% conﬁdence belts of the prediction did not overlap with
those of the experimentally observedmixture effects. All statistical anal-
yseswere performedusing the SAS statistical software (SAS Institute Inc.,
Cary, NC, USA).
Results
All three 30 componentmixtures showed AR antagonistic activity in a
dose-dependentmanner (Figs. 1A–C). As themixture ratios changed from
the IC01 to the IC20 mixtures, the concentration–response relationships
shifted towards lower concentrations, and exhibited shallower gradients
(Figs. 1A–C, Table 2). Eachof the threemixtures also displayed androgenic
activity in the concentration ranges associated with approximately half-
maximal suppressions of DHT androgenicity (insets and red bars in
Fig. 1). As judged by the decrease in luminescence in exposures without
DHT, cytotoxicity became apparent at total mixture concentrations ex-
ceeding 60 to 70 μM(Supplementalmaterial, Table S3), at concentrations
around those required for 50% inhibition of AR antagonistic effects
(Figs. 1A–C, Table 2).
Due to the large number ofmixture components,we observed striking
lowdose combination effects. For example, the individual IC01 levels of all
30 compounds summed up to a total mixture concentration of 159 μM,
which produced a 100% inhibition of the agonistic effects of DHT
(Fig. 1A). Conversely, the concentrations of all components at the point
where the IC01 mixture produced a 10% inhibition level were lower by
a factor of 5.8 than their corresponding individual IC01 concentrations
(Table 1). At such low concentrations, it would be impossible to demon-
strate any effects of the individual compounds in the MDA-kb2 assay,
yet directly measurable combination effects were produced. Similarstic compoundswithmixture ratios proportional to the effect concentrations of all mixture
ffect, IC10 (B) and a 20% antagonistic effect, IC20 (C). Observedmixture effects are from at
ean ± standard deviation). Red lines are regression ﬁts of the observed mixture effects.
ht green lines show the continuation of the CA predictions assuming that benzo(a)pyrene
seenwith DHT. Predicted effects according to IA are shown as solid blue lines. Dotted lines
rey lines show the effects of the single compounds scaled to the concentrations of the total
as red bars above the concentration axis, concentration ranges associated with cytotoxicity
dividual concentrations of the compounds are present at concentrations associated with
of the tested mixtures in the absence of DHT, together with the estimated mean effect
oncentrations and the y axis shows the luminescence value normalised to themean solvent
the y axis) indicates cytotoxicity.
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mixture (Table 2).
For the three testedmixtures, we found that the concept of IA pro-
duced concentration–response curveswithmedian effect concentrations
4.5- to 3-fold higher than those derived from CA. In addition, while the
curves predicted by CA did not differ much for the three mixtures, the
IA curves changed slightly towards lower median effect concentrations
as the mixture ratio changed from IC01 to IC20 (Fig. 1). The experimen-
tally observed anti-androgenic effects of all three mixtures fell between
the window deﬁned by the CA and IA predictions, but came closer to
the responses anticipated by CA. The closest agreement between exper-
iment and CA prediction was observed with the IC20mixture where the
measured effect concentrationswere approximately 1.3–1.5 times larger
than those predicted. In all cases, IA underestimated the experimentally
observed effects by a larger margin, with predicted effect concentrations
2–4 times higher than those observed (Table 2).
Discussion
Our study is the ﬁrst to demonstrate in vitro combination effects of
mixtures containing a large number of current use AR antagonistic
pesticides and a variety of other chemicalswith AR antagonist properties.
All the chemicals in the mixtures are relevant to human exposures typi-
cally experienced in industrialised countries, including the European
Union and the USA (see: Ermler et al., 2011; Orton et al., 2011). Our
experiments show that large numbers of AR antagonistic chemicals can
act jointly at the receptor level when present at concentrations not asso-
ciated with observable AR antagonism alone. Their joint AR antagonistic
effects occurred at concentrations of the individual components that, if
tested alone, would have produced effect magnitudes well below 1%.
Such effects are too small to be measurable with the power afforded by
the MDA-kb2 assay (Ermler et al., 2010). These observations are of
relevance in light of realistic environmental exposure scenarios where
multiple chemicals are present at low concentrations. With the excep-
tion of vinclozolin (e.g. Hass et al., 2007), none of the chemicals in our
mixtures have been tested in vivo for their ability to produce effects
typically observed with AR antagonists, it is therefore difﬁcult to say
whether any of our selected chemicals, or their mixtures, will produce
anti-androgenicity in vivo. Even so, our work shows that they have the
capability to elicit anti-androgenic effects if they reach the AR in sufﬁ-
cient quantities. Whether this is likely to happen may depend largely
on toxicokinetic factors, which are currently unexplored.
Due to a lack of biomonitoring data for pollutants that occur together
in human tissues, the number and composition of actual human expo-
sures to xenobiotics with AR antagonistic properties remains largely
unknown. The risks from AR antagonists stem mostly from exposures
in foetal life, and for this reason, the exposures experienced by pregnant
women are of particular relevance. Two recent publications have given
an impression of the combined xenobiotic exposures of pregnant
women (Castorina et al., 2010; Woodruff et al., 2011). Castorina and
co-authors focused on pesticide metabolites in urine, and showed that
of the 34 metabolites measured, 7 were detected in over 50% of partici-
pants. In this study, positive correlations between some measured
analytes were seen, indicating that individuals were exposed to several
compounds simultaneously. Woodruff and co-authors reported that
the serum of individuals tested for 52 xenobiotics contained a median
of 37 compounds (range: 28–45) and those tested for 71 contained a
median of 50 compounds (range: 35–60). It appears therefore that
co-occurrence of 30 chemicals may be a quite realistic representation
of the number of xenobiotics likely to be present in pregnant women
in the North American population. Somewhat similar results have
been reported from Europe, where 8 out of 11 phthalates/phenols in
urine from Spanish pregnant women were detected in all samples
(Casas et al., 2011) and UV-ﬁlters, synthetic musks, parabens and
phthalates were each detected in over 50% ofmilk samples from nursing
mothers in Switzerland (Schlumpf et al., 2010).Our demonstrations of combination effects of diverseAR antagonists
may provide a starting point for deﬁning common assessment
groups of AR antagonists in cumulative risk assessment. Ideally, such
groupings should be deﬁned on the basis of in vivo demonstrations of
antiandrogenicity, but in the absence of such data, in vitro ﬁndings can
give someorientation for setting priorities. Common assessment groups
have traditionally been deﬁned on the basis of mechanistic criteria and
have resulted in groupings with very similar chemical structures. For
example, US EPA currently conducts cumulative risk assessment for
ﬁve groups of pesticides: organophosphorus compounds, N-methyl
carbamates, s-triazines, chloroacetanilides and pyrethrins/pyrethroids
(USEPA, 2006a, 2006b, 2006c, 2007, 2011). Although they all inhibit
acetylcholinesterase, organophosphates and N-methyl carbamates are
not evaluated in one group, presumable because carbamylation of the
enzyme by carbamates results in rapid recovery not seen with organo-
phosphates. A report on cumulative risk assessment for phthalates and
other anti-androgenic chemicals by the US National Research Council
discussed the problems associated with using too narrowly focused
mechanistic criteria as the basis for groupings and noted that combina-
tion effects arise from several phthalates together with other, structur-
ally diverse anti-androgens, including AR antagonists (NRC, 2008). The
US National Research Council proposed a physiological grouping con-
cept based on common adverse outcomes and recognised that such
grouping criteria go far beyond the criteria derived from similarities in
chemical structures. Very recently, similar approaches have been elabo-
rated by the European Food Safety Authority (EFSA, 2013). Our ﬁndings
support the grouping philosophy proposed by US NRC and EFSA. Due to
the features of the AR binding domain, which can accommodate a
multitude of chemical structures, assessment groups for this class of
agents will have to be based on common outcomes. We propose that
the propensity of antagonising the AR in vitro provides a useful starting
point for creating such groupings which can be reﬁned on the basis of
in vivo evidence for anti-androgenicity, as and when such evidence is
forthcoming.
With predictions based on theAR antagonistic effects of the individual
mixture components, the concept of CA provided reasonable approxima-
tions of the experimentally observed combined effects, although the
agreement between prediction and observation was not perfect. The
observed mixture effects fell somewhat short of those anticipated by
CA, nevertheless, the joint effects of all three mixture ratios were consid-
erably stronger than those anticipated by IA. We suggest that the slight
shortfalls between the observed cumulative effects and the CA predic-
tionsmaybe related to the fact that AR antagonists frequently also exhibit
AR agonist properties at higher concentrations (Tamura et al., 2006).
Several of the chemicals included in the mixtures fall in that category
(Ermler et al., 2011; Orton et al., 2011) and the AR agonistic effects of
these mixtures overlapped with the concentration ranges where AR
antagonistic effects occurred (Fig. 1, insets). We have previously shown
that when chemicals with dual AR agonist and antagonist properties
are excluded from themixtures, and only “pure”AR antagonists are com-
bined, perfect agreement with CA can be obtained (Orton et al., 2012).
Since the combination effect predictions are based on the AR antagonist
concentration response curves of the single mixture components, the
prediction concepts themselves have no facilities to directly account for
AR agonism (exposure in the absence of DHT). However, agonistic effects
would be indirectly accounted for under the assumption that competing
agonist and antagonist effects both contribute to the antagonist concen-
tration response curve, provided that competition is occurring at the
same target. We previously showed that when dual action antagonists
are included in the mixture, observed deviation is not the result of com-
petition at the ligand binding domain of the AR, but rather unidentiﬁed
factors cause this phenomenon (Orton et al., 2012). Since the same pesti-
cides as reported in Orton et al. are included in the mixtures tested here,
as well as other dual action AR antagonists (Ermler et al., 2011), we
hypothesise that similar explanations account for the observed deviation
from CA.
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We have shown that the anti-androgenic effects of a mixture of AR
antagonists fromawide rangeof sources andexposure routes are additive
in this assay at very low concentrations. Since our compound selection
was based on either actual or estimated human exposure in Europe and
the USA, at least some of themixture components are likely to be present
simultaneously in people.Whether combined effects fromexposure to AR
antagonists might be produced in foetal life, thus providing a possible
explanation for the rising trends in cryptorchidisms and hypospadias,
will be determined by the number of AR antagonists present in tissues
and their potency. However, our study has shown that the often low
levels measured for individual AR antagonists are not a reliable indicator
for dismissing risks from this class of chemicals. Renewed efforts of
searching for AR antagonists in human tissuewill be required for cumula-
tive risk assessment.
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